Ascending Single-Dose Study of the Safety Profile, Tolerability, and Pharmacokinetics of Bosutinib Coadministered With Ketoconazole to Healthy Adult Subjects

Clinical Therapeutics

Volumn 34, Issue 9, 2012, Pages

  Abbas, Richat ^a   Leister, Cathie ^a   Gaaloul, Myriam El ^a   Chalon, Stephan ^a   Sonnichsen, Daryl ^a  

^a PFIZER INC   (United States)

Author keywords

Bosutinib; Ketoconazole; Pharmacokinetics; Tyrosine kinase inhibitor

Indexed keywords

BOSUTINIB; KETOCONAZOLE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; CLINICAL ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERHIDROSIS; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NECK PAIN; NORMAL HUMAN; OROPHARYNX PAIN; ORTHOSTATIC HYPERTENSION; PALLOR; PHASE 1 CLINICAL TRIAL; POSITIONAL DIZZINESS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; STOMATITIS; VOMITING;

EID: 84866162166     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.07.006     Document Type: Article

References (26)

1. Golas J.M., Arndt K., Etienne C., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63:375-381.
2. Puttini M., Coluccia A.M., Boschelli F., et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006, 66:11314-11322.
3. Boschelli D.H., Wang Y.D., Johnson S., et al. 7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases. J Med Chem 2004, 47:1599-1601.
4. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13:513-609.
5. Avizienyte E., Frame M.C. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005, 17:542-547.
6. Windham T.C., Parikh N.U., Siwak D.R., et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002, 21:7797-7807.
7. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007, 18:1765-1773.
8. Kurzrock R., Kantarjian H.M., Druker B.J., Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003, 138:819-830.
9. Khoury H.J., Cortes J.E., Kantarjian H.M., et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012, 119:3403-3412.
10. Cortes J.E., Kantarjian H.M., Brummendorf T.H., et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
11. Gambacorti-Passerini C., Cortes J.E., Khoury H.J., et al. Safety and efficacy of bosutinib in patients with AP and BP CML and Ph+ ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol 2010, 28. Abstract 6509.
12. Cortes J.E., Kim Dong, Kantarjian H.M., et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012, In press.
13. ClinicalTrialsFeeds.org US National Institutes of Health, Accessed March 27, 2012. http://clinicaltrialsfeeds.org/clinical-trials/results/term=bosutinib.
14. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000, 38:41-57.
15. Bjornsson T.D., Callaghan J.T., Einolf H.J., et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003, 43:443-469.
16. Abbas R., Hug B.A., Leister C., et al. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol 2012, 69:221-227.
17. Abbas R., Hug B.A., Leister C., et al. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 2011, 51:1721-1727.
18. Hug B., Abbas R., Leister C., Burns J., Sonnichsen D. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin Cancer Res 2010, 16:4016-4023.
19. Guidance for industry. E6 Good Clinical Practice: consolidated guidance, April 1996 US Food and Drug Administration, Accessed March 29, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf.
20. Evans W.E., Schentag J.J., Jusko W.J. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring 1992, Lippincott Williams & Wilkins, Vancouver, BC, Canada.
21. Chien J.Y., Lucksiri A., Ernest C.S., et al. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 2006, 34:1208-1219.
22. Oo C., Chen Y.C. The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. J Clin Pharmacol 2009, 49:368-369.
23. Gambacorti-Passerini C., Brummendorf T.H., Kantarjian H., et al. Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. J Clin Oncol 2007, 25:7006.
24. Glassman A.H., Bigger J.T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001, 158:1774-1782.
25. Shah R.R. The significance of QT interval in drug development. Br J Clin Pharmacol 2002, 54:188-202.
26. International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist 2005, 70:61134-61135. Food and Drug Administration, HHS.